Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Selection of Candesartan and Amlodipine in Essential Hypertension
NCT02059616Phase 2Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Feb 2014
- Primary completion
- Jun 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of candesartan cilexetil and amlodipine in essential hypertension (8 arms), sponsored by HK inno.N Corporation. Primary endpoint: Change in sitting Diastolic Blood Pressure at 8 weeks. Status: unknown.
02
Drugs
candesartan cilexetilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02059616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059616.